Differential effect of MMSET mRNA levels on survival to first-line FOLFOX and second-line docetaxel in gastric cancer

Wei, Jia; Costa, Carlota; Shen, Jie; Yu, Lan; Sánchez, José Javier; Qian, Xiaoping; Sun, Xuan; Zou, Zhengyun; Giménez‐Capitán, Ana; Yue, Guofeng; Guan, Wei; Rosell, Rafael; Liu, B

doi:10.1038/bjc.2014.231

Cited by 8 publications

(6 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, they did notice a strong association between mRNA expression of BIM and OS in a subset of patients who received second-line docetaxel-based chemotherapy. Similar findings have been observed in other studies [ 122 , 123 ]. This shows that the association between mRNA expression and OS in gastric cancer can be affected by chemotherapy and is also dependant on the chemotherapeutic agents used.…”

Section: Discussionsupporting

confidence: 93%

Proteomic Signatures of Diffuse and Intestinal Subtypes of Gastric Cancer

Singh

Bhat

Sathe

et al. 2021

Cancers

View full text Add to dashboard Cite

Gastric cancer is a leading cause of death from cancer globally. Gastric cancer is classified into intestinal, diffuse and indeterminate subtypes based on histology according to the Laurén classification. The intestinal and diffuse subtypes, although different in histology, demographics and outcomes, are still treated in the same fashion. This study was designed to discover proteomic signatures of diffuse and intestinal subtypes. Mass spectrometry-based proteomics using tandem mass tags (TMT)-based multiplexed analysis was used to identify proteins in tumor tissues from patients with diffuse or intestinal gastric cancer with adjacent normal tissue control. A total of 7448 or 4846 proteins were identified from intestinal or diffuse subtype, respectively. This quantitative mass spectrometric analysis defined a proteomic signature of differential expression across the two subtypes, which included gremlin1 (GREM1), bcl-2-associated athanogene 2 (BAG2), olfactomedin 4 (OLFM4), thyroid hormone receptor interacting protein 6 (TRIP6) and melanoma-associated antigen 9 (MAGE-A9) proteins. Although GREM1, BAG2, OLFM4, TRIP6 and MAGE-A9 have all been previously implicated in tumor progression and metastasis, they have not been linked to intestinal or diffuse subtypes of gastric cancer. Using immunohistochemical labelling of a tissue microarray comprising of 124 cases of gastric cancer, we validated the proteomic signature obtained by mass spectrometry in the discovery cohort. Our findings should help investigate the pathogenesis of these gastric cancer subtypes and potentially lead to strategies for early diagnosis and treatment.

show abstract

Section: Discussionsupporting

confidence: 93%

Proteomic Signatures of Diffuse and Intestinal Subtypes of Gastric Cancer

Singh

Bhat

Sathe

et al. 2021

Cancers

View full text Add to dashboard Cite

show abstract

“…The present authors previously observed that GC patients with high BRCA1 levels could benefit from receiving second-line docetaxel-based chemotherapy (6). In addition, the median OS was further prolonged for patients with high levels of BRCA1 and multiple myeloma SET domain (39). The DNA damage caused by chemotherapy leads to cell cycle arrest, DNA repair or commitment to apoptosis (40).…”

Section: Discussionmentioning

confidence: 72%

High BIM mRNA levels are associated with longer survival in advanced gastric cancer

Huang

Zou

et al. 2017

Oncology Letters

View full text Add to dashboard Cite

Abstract. Chemotherapy drugs, including 5-fluorouracil (5-FU), oxaliplatin and docetaxel, are commonly used in the treatment of gastric cancer (GC). Apoptosis-relevant genes may be associated with drug resistance. In the present study, the messenger RNA (mRNA) expression levels of B-cell lymphoma 2 interacting mediator of cell death (BIM), astrocyte elevated gene-1 (AEG-1) and AXL receptor tyrosine kinase (AXL) were investigated in 131 advanced GC samples, and the expression levels of these genes were correlated with patients' overall survival (OS). All 131 patients received first-line FOLFOX combination chemotherapy with folinic acid and 5-FU, in which 56 patients were further treated with second-line docetaxel-based chemotherapy. A correlation between the mRNA expression levels of BIM and AEG-1 was observed (r s =0.30; P=0.002). There was no association between the mRNA expression levels of any of the individual genes analyzed and OS in patients only receiving first-line FOLFOX chemotherapy. In a subgroup of patients receiving docetaxel-based second-line chemotherapy, those with high or intermediate levels of BIM exhibited a median OS of 18.2 months [95% confidence interval (CI), 12.8-23.6], compared with 9.6 months (95% CI, 8.9-10.3) in patients with low BIM levels (P=0.008). However, there was no correlation between the mRNA expression levels of AEG-1 or AXL and OS. The risk of mortality was higher in patients with low BIM mRNA levels than in those with high or intermediate BIM mRNA levels (hazard ratio, 2.61; 95% CI, 1.21-5.62; P=0.010). Therefore, BIM may be considered as a biomarker to identify whether patients could benefit from docetaxel-based second-line chemotherapy in GC.

show abstract

“…Relative gene expression quantifications were calculated according to the comparative Ct method using β-actin as an endogenous control and commercial human lung and liver RNA (Stratagene, La Jolla, CA, USA) as calibrators. Final results were determined by the formula 2 -(ΔCtsample-ΔCtcalibrator) and were performed according to Technical Bulletin #2 (Applied Biosystems) ( 9 ).…”

Section: Methodsmentioning

confidence: 99%

Therapeutic effect and safety of individualized chemotherapy combined with sequential immunotherapy based on BRCA1 mRNA expression level in unresectable pancreatic cancer

Zhu

Sha

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

AimWe aimed to evaluate the efficacy and safety of individualized chemotherapy combined with sequential immunotherapy based on BRCA1 mRNA expression in unresectable pancreatic cancer.MethodsThe expression of BRCA1 mRNA in tumor tissues of 25 patients with pancreatic cancer was detected in this retrospective study. Patients in the medium and high expression groups were treated with paclitaxel-based chemotherapy: albumin paclitaxel 125mg/m2, gemcitabine 1g/m2, day 1. Patients in the low expression group were treated with oxaliplatin-based chemotherapy: oxaliplatin 85mg/m2, gemcitabine 1g/m2, day 1. Sequential GM-CSF and IL-2 immunotherapy were applied. Patient condition, treatment efficacy and safety were assessed every 4 cycles.ResultsA total of 25 patients were enrolled in the study. All of them were observed for toxic side effects and 24 of them were evaluated for efficacy. The median overall survival and median progression-free survival were 11.9 months and 6.3 months. The disease control rate was 91.7%, of which 37.5% (9/24) patients achieved partial remission (PR), 54.2% (13/24) patients achieved stable disease (SD) and 8.3% (2/24) patients were assessed as progressive disease(PD). Of the 15 patients with medium or high expression in BRCA1 mRNA, 7 achieved PR and 8 achieved SD. Of the 9 patients with low BRCA1 mRNA expression, 2 achieved PR, 5 achieved SD and 2 had PD. The proportion of eosinophils in the blood of some patients with good therapeutic effects was significantly higher than that before treatment. Hematological and non-hematological toxicity during the treatment were mostly grade 1~2. The two most common grade 3 to 4 adverse events were fever and thrombocytopenia.ConclusionOur results suggest that individualized selection of chemotherapy combined with sequential immunotherapy according to BRCA1 mRNA expression level in unresectable pancreatic cancer could control the disease and have controllable adverse reactions.

show abstract

Differential effect of MMSET mRNA levels on survival to first-line FOLFOX and second-line docetaxel in gastric cancer

Cited by 8 publications

References 34 publications

Proteomic Signatures of Diffuse and Intestinal Subtypes of Gastric Cancer

Proteomic Signatures of Diffuse and Intestinal Subtypes of Gastric Cancer

High BIM mRNA levels are associated with longer survival in advanced gastric cancer

Therapeutic effect and safety of individualized chemotherapy combined with sequential immunotherapy based on BRCA1 mRNA expression level in unresectable pancreatic cancer

Contact Info

Product

Resources

About